Women's Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Sep 12, 2011, 05:40 ET from Reportlinker

NEW YORK, Sept. 12, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Women's Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0611548/Women's-Infertility-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Hardware,_Home_Improvement_&_Furnishing_Stores

Women's Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Women's Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Women's Infertility Therapeutics market. The report identifies the key trends shaping and driving the global Women's Infertility Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Women's Infertility Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Women's Infertility Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Women's Infertility Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Women's Infertility Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Women's Infertility Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Women's Infertility Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Women's Infertility Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Women's Infertility Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Women's Infertility Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Women's Infertility Therapeutics - Introduction 6

2.1 Overview 6

2.1.1 Quality of Life 7

2.2 Epidemiology 7

2.3 Etiology and Pathophysiology 7

2.4 Signs and Symptoms 9

2.5 Diagnosis 9

2.6 Treatment and Management 10

2.7 GlobalData Pipeline Report Guidance 12

3 Women's Infertility Therapeutics - Market Characterization 13

3.1 Overview 13

3.2 Women's Infertility Therapeutics Market Size (2005-2010) - Global 13

3.3 Women's Infertility Therapeutics Market Forecast (2010-2018) - Global 14

3.4 Women's Infertility Therapeutics Market Size (2005-2010) - The US 15

3.5 Women's Infertility Therapeutics Market Forecast (2010-2018) - The US 16

3.6 Women's Infertility Therapeutics Market Size (2005-2010) - France 17

3.7 Women's Infertility Therapeutics Market Forecast (2010-2018) - France 18

3.8 Women's Infertility Therapeutics Market Size (2005-2010) - Germany 19

3.9 Women's Infertility Therapeutics Market Forecast (2010-2018) - Germany 20

3.10 Women's Infertility Therapeutics Market Size (2005-2010) - Italy 21

3.11 Women's Infertility Therapeutics Market Forecast (2010-2018) - Italy 22

3.12 Women's Infertility Therapeutics Market Size (2005-2010) - Spain 23

3.13 Women's Infertility Therapeutics Market Forecast (2010-2018) - Spain 24

3.14 Women's Infertility Therapeutics Market Size (2005-2010) - The UK 25

3.15 Women's Infertility Therapeutics Market Forecast (2010-2018) - The UK 26

3.16 Women's Infertility Therapeutics Market Size (2005-2010) - Japan 27

3.17 Women's Infertility Therapeutics Market Forecast (2010-2018) - Japan 28

3.18 Drivers and Barriers for the Women's Infertility Therapeutics Market 29

3.18.1 Drivers for the Women's Infertility Therapeutics Market 29

3.18.2 Barriers for the Women's Infertility Therapeutics Market 29

3.19 Opportunity and Unmet Need 30

3.20 Key Takeaway 30

4 Women's Infertility Therapeutics - Competitive Assessment 31

4.1 Overview 31

4.1.1 Strategic Competitor Assessment 31

4.2 Women's Infertility Market, Marketed Products Profile 32

4.2.1 Ovidrel (choriogonadotropin alfa) 32

4.2.2 Gonal-f (follitropin alfa) 33

4.2.3 Cetrotide (cetrorelix acetate) 36

4.2.4 Luveris (lutropin alfa) 38

4.2.5 Elonva (corifollitropin alfa injection) 40

4.3 Key Takeaway 41

5 Women's Infertility Therapeutics - Pipeline Assessment 42

5.1 Overview 42

5.2 Strategic Pipeline Assessment 42

5.3 Women's Infertility Therapeutics Pipeline - Pipeline by Phases of Development 42

5.3.1 Women's Infertility Therapeutics - Phase III and NDA Filed Pipeline 42

5.3.2 Women's Infertility Therapeutics - Phase II Pipeline 43

5.3.3 Women's Infertility Therapeutics - Phase I Pipeline 43

5.3.4 Women's Infertility Therapeutics - Preclinical and Discovery Pipeline 43

5.4 Women's Infertility Therapeutics Market - Clinical Pipeline by Mechanism of Action 44

5.5 Technology Trends Analytical Framework 45

5.6 Women's Infertility Therapeutics - Promising Drugs Under Clinical Development 46

5.7 Molecule Profiles for Promising Drugs Under Clinical Development 47

5.7.1 Progesterone Vaginal Ring 47

5.7.2 DA-3801 (rFSH) 47

5.7.3 Afolia (follitropin alfa) 48

5.8 Key Takeaway 48

6 Women's Infertility Therapeutics - Clinical Trials Mapping 49

6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 49

6.2 Clinical Trials by Phase 50

6.3 Clinical Trials by Trial Status 51

6.4 Prominent Sponsors 52

6.5 Top Companies Participating in Women's Infertility Therapeutics Clinical Trials 54

7 Women's Infertility Therapeutics - Strategic Assessment 55

7.1 Key Events Impacting the Future Market 55

7.2 Women's Infertility Therapeutics - Implications for Future Market 55

8 Women's Infertility Therapeutics - Future Players 57

8.1 Introduction 57

8.2 Merck and Co., Inc. 58

8.2.1 Company Overview 58

8.2.2 Business Description 58

8.2.3 Women Infertility Pipeline 59

8.3 Dong-A Pharmaceutical Co. Ltd. 60

8.3.1 Company overview 60

8.3.2 Business Description 60

8.3.3 Women's Infertility Pipeline 61

8.4 Teva Pharmaceutical Industries Limited 62

8.4.1 Company Overview 62

8.4.2 Business description 62

8.4.3 Women's Infertility Pipeline 63

8.5 Gedeon Richter Plc 64

8.5.1 Overview 64

8.5.2 Business Description 64

8.5.3 Women's Infertility Pipeline 65

9 Licensing and Partnership Deals 66

10 Global Women's Infertility Market - Appendix 68

10.1 Market Definitions 68

10.2 Abbreviations 68

10.3 Research Methodology 69

10.3.1 Coverage 69

10.3.2 Secondary Research 69

10.3.3 Forecasting 70

10.3.4 Primary Research 72

10.3.5 Expert Panels 72

10.4 Contact Us 72

10.5 Disclaimer 72

10.6 Bibliography 73

1.1 List of Tables

Table 1: Types of Women's Infertility 7

Table 2: Women's Infertility Therapeutics, Global, Market Revenue ($m), 2005-2010 13

Table 3: Women's Infertility Therapeutics, Global, Revenue Forecasts ($m), 2010-2018 14

Table 4: Women's Infertility Therapeutics Market, The US, Revenue ($m), 2005-2010 15

Table 5: Women's Infertility Therapeutics Market, The US, Revenue ($m), 2010-2018 16

Table 6: Women's Infertility Therapeutics, France, Market Revenue ($m), 2005-2010 17

Table 7: Women's Infertility Therapeutics, France, Revenue Forecasts ($m), 2010-2018 18

Table 8: Women's Infertility Therapeutics, Germany, Market Revenue ($m), 2005-2010 19

Table 9: Women's Infertility Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018 20

Table 10: Women's Infertility Therapeutics, Italy, Market Revenue ($m), 2005-2010 21

Table 11: Women's Infertility Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018 22

Table 12: Women's Infertility Therapeutics, Spain, Market Revenue ($m), 2005-2010 23

Table 13: Women's Infertility Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018 24

Table 14: Women's Infertility Therapeutics, the UK, Market Revenue ($m), 2005-2010 25

Table 15: Infertility Therapeutics, the UK, Revenue Forecasts ($m), 2010-2018 26

Table 16: Women's Infertility Therapeutics Market, Japan, Revenue ($m), 2005-2010 27

Table 17: Women's Infertility Therapeutics Market, Japan, Forecast ($m), 2010-2018 28

Table 18: Efficacy Outcomes of r-hCG in ART 32

Table 19: Ovulation and Clinical Pregnancy Rates by Treatment Group in Ovulation Induction 34

Table 20: Pregnancy Outcome by Treatment Group in Ovulation Induction 35

Table 21: Patient Ovulation and Clinical Pregnancy Rates by Treatment Group 35

Table 22: Pregnancy Outcome by Treatment Group in Ovulation Induction 35

Table 23: Pregnancy Outcome by Treatment Group in ART 36

Table 24: Pregnancy Outcome by Treatment Group in ART 36

Table 25: Results of Phase III Clinical Studies with Cetrotide 3mg in a Single Dose Regimen and 0.25mg in a Multiple Dose Regimen 37

Table 26: Follicular Development Rate 38

Table 27: Secondary Efficacy Parameters 39

Table 28: Follicular Development Rate 39

Table 29: Secondary Efficacy Parameters 39

Table 30: Cumulative Follicular Development Rate 40

Table 31: Primary Efficacy Variable 40

Table 32: Pregnancy Rate in the 150mcg Trial 41

Table 33: Women's Infertility Therapeutics - Phase III and NDA Filed Pipeline, 2011 42

Table 34: Women's Infertility Therapeutics - Phase II Pipeline, 2011 43

Table 35: Women's Infertility Therapeutics - Phase I Pipeline, 2011 43

Table 36: Women's Infertility Therapeutics - Discovery and Preclinical Pipeline, 2011 43

Table 37: Women's Infertility Therapeutics - Most Promising Drugs Under Clinical Development, 2011 46

Table 38: Women's Infertility Therapeutics - Clinical Trials by Country, 2011 49

Table 39: Women's Infertility Therapeutics - Clinical Trials by Phase, 2011 50

Table 40: Women's Infertility Therapeutics - Clinical Trials by Status, 2011 51

Table 41: Women Infertility Therapeutics - Prominent Sponsors, 2011 53

Table 42: Women's Infertility Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 54

Table 43: Merck & Co., Inc. - Women's Healthcare Pipeline Products, 2011 59

Table 44: Merck & Co., Inc - Women's Infertility Pipeline Portfolio, 2011 59

Table 45: Dong-A Pharmaceutical Co., Ltd - Women's Health Pipeline Portfolio, 2011 61

Table 46: Dong-A Pharmaceutical Co., Ltd - Women's Infertility Pipeline Portfolio, 2011 61

Table 47: Teva Pharmaceutical Industries Limited - Women's Health Pipeline Portfolio, 2011 63

Table 48: Teva Pharmaceutical Industries Limited - Women's Infertility Pipeline Portfolio, 2011 63

Table 49: Gedeon Richter Plc - Women's Health Pipeline Portfolio, 2011 65

Table 50: Gedeon Richter Plc - Women's Infertility Pipeline Portfolio, 2011 65

Table 51: Women's Infertility Therapeutics, Global, Deals, 2009-2011 66

1.2 List of Figures

Figure 1: The Reproduction Process from Ovulation to Implantation 6

Figure 2: Distribution of Cause(s) of Infertility 6

Figure 3: Causes of Women's Infertility 7

Figure 4: Pathophysiology of Infertility 8

Figure 5: Treatment Algorithm for Women's Infertility 10

Figure 6: Women's Infertility Therapeutics, Global, Market Revenue ($m), 2005-2010 13

Figure 7: Women's Infertility Therapeutics, Global, Market Revenue ($m), 2010-2018 14

Figure 8: Women's Infertility Therapeutics Market, The US, Revenue ($m), 2005-2010 15

Figure 9: Women's Infertility Therapeutics Market, The US, Forecast ($m), 2010-2018 16

Figure 10: Women's Infertility Therapeutics Market, France, Revenue ($m), 2005-2010 17

Figure 11: Women's Infertility Therapeutics, France, Revenue Forecasts ($m), 2010-2018 18

Figure 12: Women's Infertility Therapeutics Market, Germany, Revenue ($m), 2005-2010 19

Figure 13: Women's Infertility Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018 20

Figure 14: Women's Infertility Therapeutics, Italy, Market Revenue ($m), 2005-2010 21

Figure 15: Women's Infertility Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018 22

Figure 16: Women's Infertility Therapeutics, Spain, Market Revenue ($m), 2005-2010 23

Figure 17: Women's Infertility Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018 24

Figure 18: Women's Infertility Therapeutics, the UK, Market Revenue ($m), 2005-2010 25

Figure 19: Women's Infertility Therapeutics, the UK, Revenue Forecasts ($m), 2010-2018 26

Figure 20: Women's Infertility Therapeutics, Japan, Market Revenue ($m), 2005-2010 27

Figure 21: Women's Infertility Therapeutics Market, Japan, Forecast ($m), 2010-2018 28

Figure 22: Opportunity and Unmet Need in the Women's Infertility Therapeutic Market, 2010 30

Figure 23: Strategic Competitor Assessment of Marketed Products for Women's Infertility, 2010 31

Figure 24: Women's Infertility Therapeutics - Pipeline by Phase of Development, 2011 42

Figure 25: Women's Infertility Market - Clinical Pipeline by Mechanism of Action, 2011 44

Figure 26: Women's Infertility Therapeutics - Technology Trends Analytics Framework, 2011 45

Figure 27: Women's Infertility Therapeutics - Technology Trends Analytics Framework - Description, 2011 46

Figure 28: Women's Infertility Clinical Trials by Region, 2011 49

Figure 29: Women's Infertility Clinical Trials by Phase, 2011 50

Figure 30: Women's Infertility Therapeutics - Clinical Trials by Status, 2011 51

Figure 31: Women's Infertility Therapeutics - Overall Sponsors, 2011 52

Figure 32: Women's Infertility Therapeutics - Prominent Sponsors, 2011 52

Figure 33: Women's Infertility Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 54

Figure 34: Women's Infertility Therapeutics, Drivers and Barriers, 2011 55

Figure 35: Implications for Future Market Competition in the Women's Infertility Therapeutics Market, 2011 55

Figure 36: Women's Infertility Therapeutics, Clinical Pipeline by Company, 2011 57

Figure 37: GlobalData Market Forecasting Model 71

Companies mentioned

Merck and Co., Inc.

Dong-A Pharmaceutical Co. Ltd.

Teva Pharmaceutical Industries Limited

Gedeon Richter Plc

To order this report:

Hardware, Home Improvement & Furnishing Stores Industry: Women's Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Hardware, Home Improvement & Furnishing Stores Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com